Clinical Trials on Influenza, Human

Total 8046 results

National Institute of Allergy and Infectious Diseases...

Completed

Nontypeable H. Influenzae in Healthy Adults

Haemophilus Influenzae (NTHI)

United States
GlaxoSmithKline

Completed

3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age

Neisseria Meningitidis | Haemophilus Influenzae Type b

Belgium, Germany
GlaxoSmithKline

Completed

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States, Mexico
Centers for Disease Control and Prevention
National Institute of Allergy and Infectious Diseases (NIAID); Alaska Native... and other collaborators

Completed

Study to Eliminate Hib Carriage in Rural Alaska Native Villages

Haemophilus Influenzae Type B | Carrier State

United States
Alios Biopharma Inc.

Completed

A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872

Influenza in Humans

United Kingdom
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States, Australia, Mexico
Johns Hopkins Bloomberg School of Public Health
Merck Sharp & Dohme LLC

Completed

Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study)

Haemophilus Influenzae Type B Infection

United States
Beijing Minhai Biotechnology Co., Ltd

Unknown

Safety and Immunogenicity of Haemophilus Influenzae Type b Conjugate Vaccine，Freeze-dried

Haemophilus Influenzae Type b Infections

China
Novartis Vaccines

Completed

Safety of Haemophilus Influenza Type b Vaccine When Administered to Korean Children

Haemophilus Influenzae Type B Infection

Korea, Republic of
Lieselot Houspie

Unknown

Nasal Specimen Collection Study in Patients With ILI and/or ARI in an Outpatient Setting

Influenza-like Illness | Influenzal Acute Respiratory Infection

Belgium
University of Maryland
National Institute of Allergy and Infectious Diseases (NIAID); Centers for...

Completed

Evaluating Modes of Influenza Transmission Observational Study of Community Acquired Influenza (EMIT)

Influenza Virus Infection Transmission in Humans

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers

Respiratory Disorders

Belgium
GlaxoSmithKline

Completed

Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine

Respiratory Disorders

Australia
Merck Sharp & Dohme LLC

Completed

Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED)

Hepatitis B | Haemophilus Influenzae Type B
Novartis Vaccines

Completed

Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects

Influenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza Virus

Belgium
GlaxoSmithKline

Completed

Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b | Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine

Poland, United Kingdom
Novartis Vaccines

Completed

Safety and Reactogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b

Haemophilus Influenzae Type b

China
AVIR Green Hills Biotechnology AG

Completed

Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB01L1 in Healthy Volunteers (GHBCS-01)

Seasonal Human Influenza

Austria
Novartis Vaccines

Completed

Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b

Haemophilus Influenzae Type b

China
GlaxoSmithKline

Completed

Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

Australia
University of Versailles
Assistance Publique - Hôpitaux de Paris

Terminated

Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu (CORTIFLU)

Pneumonia, Viral | Influenza in Humans

France
LG Life Sciences

Completed

Immunogenicity and Safety Study of LBVH0101 in Healthy Infants at Two, Four and Six Months of Age

Infectious Disease by Haemophilus Influenzae Type b

Korea, Republic of
Jiangsu Province Centers for Disease Control and...
Chengdu Olymvax Biopharmaceuticals Inc.

Completed

A Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine

Haemophilus Influenza
St. Petersburg Research Institute of Vaccines and...

Completed

Safety and Reactogenicity Trial of Vaccine for the Prevention of Infections Caused by Haemophilus Influenzae Type b

Vaccines | Haemophilus Influenzae Infection

Russian Federation
Emergent BioSolutions

Completed

Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)

Human Influenza

Australia
Novartis Vaccines

Completed

Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above

Human Influenza

Germany
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age

Human Influenza

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above

Human Influenza

Germany
Hualan Biological Engineering, Inc.

Completed

Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine

Human Influenza

China
Fluart Innovative Vaccine Ltd, Hungary

Completed

Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents

Human Influenza
Research Institute for Biological Safety Problems
Research Institute of Influenza, Russia; Asfendiyarov Kazakh National Medical...

Completed

Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine

Human Influenza

Kazakhstan
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above

Human Influenza

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above

Human Influenza

Belgium
Novartis
Novartis Vaccines

Completed

A Study to Evaluate Safety and Immunogenicity of Trivalent Influenza Vaccine, Formulation 2015 Southern Hemisphere, When Administered to Healthy Adult Subjects.

Human Influenza

Brazil
Butantan Institute
Fundação de Amparo à Pesquisa do Estado de São Paulo

Completed

Clinical Trial for the Evaluation of Three Regimens of Influenza Vaccination in Kidney Transplant Recipients

Human Influenza

Brazil
Centers for Disease Control and Prevention
Universidad del Valle, Guatemala; Hospital Nacional San Juan de Dios de Santa... and other collaborators

Terminated

Panama and El Salvador Children's Oseltamivir Study (PECOS)

Influenza | Human Influenza

Panama, El Salvador
Novartis Vaccines

Completed

Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects

Human Influenza

Belgium
Hualan Biological Engineering, Inc.

Completed

Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine

Human Influenza

China
Meso Scale Diagnostics, LLC.
Centers for Disease Control and Prevention

Terminated

Clinical Validation of the Point-of-Care MSD Influenza Test

Influenza Human

United States
Chinese Academy of Sciences
Jiangsu Province Centers for Disease Control and Prevention; Hualan Biological...

Unknown

Immunogenicity Study of S-OIV H1N1 Influenza Vaccine

Human Influenza

China
University of Athens
Hellenic Pasteur Institute

Completed

Influenza Vaccine Effectiveness of a Quadrivalent Vaccine in Pregnant Women and Young Infants, 2019-2020

Influenza in Human

Greece
Pantec Biosolutions AG
Medical University of Vienna

Completed

Comparison of Laser Assisted Epidermal to Intradermal Administration of Seasonal Influenza Vaccine

Influenza in Human

Austria
Assistance Publique - Hôpitaux de Paris

Completed

Face Masks for Preventing Influenza Transmission (GRIPMASK)

Influenza Human

France
University of Zurich
Schweizerischer Nationalfonds

Completed

Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting (TransFLUas)

Human Influenza

Switzerland
Novartis Vaccines

Completed

Study in Toddlers (12-18 Months) Comparing a Booster Dose of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b Infections in China

Haemophilus Influenzae Type b (Hib) Infection

China
Korea University Guro Hospital

Completed

Conventional Vaccine and Intradermal Vaccine Among HIV-infected Young Subjects

Human Influenza
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine

Influenza | Influenza, Human | Influenza A Virus, H5N1 Subtype | Flu, Human | Flu, Avian

Australia, Germany, Italy
Service de Médecine Préventive Hospitalière

Completed

Promotion of Influenza Vaccination in Healthcare Workers During the Recruitment Visit

Human Influenza Vaccination in Healthcare Workers
BioCryst Pharmaceuticals

Completed

A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza

Acute, Uncomplicated Human Influenza

United States, Australia, New Zealand, South Africa
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

Influenza, Human Prevention | Respiratory Syncytial Viruses Prevention

United States

3

Subscribe